Avalo Therapeutics, Inc. has filed a registration statement with the Securities and Exchange Commission (SEC) on June 6, 2024, for the resale of various securities by selling stockholders. The registration includes up to 22,357,897 shares of common stock issuable upon the conversion of Series C Non-Voting Convertible Preferred Stock, 22,357.897 shares of Series C Non-Voting Convertible Preferred Stock, up to 11,967,526 shares of common stock issuable upon the exercise of warrants, and warrants to purchase up to 11,967,526 shares of common stock. The securities were originally issued in connection with Avalo's acquisition of AlmataBio, Inc. on March 27, 2024, and a related private placement that closed on March 28, 2024. The Series C preferred stock and warrants are subject to a beneficial ownership limitation, preventing conversion or...Show More

Avalo Therapeutics, Inc. has filed a registration statement with the Securities and Exchange Commission (SEC) on June 6, 2024, for the resale of various securities by selling stockholders. The registration includes up to 22,357,897 shares of common stock issuable upon the conversion of Series C Non-Voting Convertible Preferred Stock, 22,357.897 shares of Series C Non-Voting Convertible Preferred Stock, up to 11,967,526 shares of common stock issuable upon the exercise of warrants, and warrants to purchase up to 11,967,526 shares of common stock. The securities were originally issued in connection with Avalo's acquisition of AlmataBio, Inc. on March 27, 2024, and a related private placement that closed on March 28, 2024. The Series C preferred stock and warrants are subject to a beneficial ownership limitation, preventing conversion or exercise that would result in ownership exceeding 9.99% or 4.99% of outstanding common stock. Avalo Therapeutics will not receive proceeds from the resale of securities by the selling stockholders but may receive proceeds from the exercise of warrants. The common stock is traded on The Nasdaq Capital Market under the symbol 'AVTX,' while the Series C preferred stock and warrants are not listed on any exchange.